Moleculin Biotech logo
Moleculin Biotech
MBRX | NASDAQ
Chart Builder DCF Calculator
$7.14
-$0.73 (-9.28%)
At close: Nov 16, 2026, 4:00 PM ET
$7.46
+$0.32 (+4.48%)
After-hours: Nov 16, 2026, 7:30 PM ET

Moleculin Biotech Company Profile

Company profile explained

Company Profile

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Key Executives

Name Position
Walter V. Klemp Chairman, President & CEO
Jonathan Foster Executive Vice President & Chief Financial Officer
Donald H. Picker Chief Scientific Officer
John Paul Waymack Senior Chief Medical Officer
Waldemar Priebe Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Oct 30, 2026 8-K Current Report
Oct 20, 2026 8-K Current Report
Oct 16, 2026 4 Filing
Oct 16, 2026 4 Filing
Oct 16, 2026 4 Filing
Oct 16, 2026 8-K Current Report
Oct 15, 2026 S-8 Filing
Oct 09, 2026 8-K Current Report
Oct 05, 2026 8-K Current Report
Sep 29, 2026 8-K Current Report
View All SEC Filings ➞
Moleculin Biotech
Moleculin Biotech logo
Country United States
IPO Date Jun 2, 2016
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Walter V. Klemp

Contact Details

5300 Memorial Drive Houston, Texas 77007 United States

Stock Details

Ticker Symbol MBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001659617
CUSIP Number 60855D507
ISIN Number US60855D5077
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.